OverviewSuggest Edit

Editas Medicine is a transformative genome editing company that is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. The Company operates through developing and commercializing genome editing technology segment. Editas Medicine is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats technology.
TypePublic
Founded2013
HQCambridge, MA, US
Websiteeditasmedicine.com
Employee Ratings3.1

Latest Updates

Employees (est.) (Feb 2020)208(+17%)
Job Openings29
Revenue (FY, 2020)$90.7 M(+342%)
Share Price (May 2022)$11.9(+10%)
Cybersecurity ratingCMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Editas Medicine

James C. Mullen

James C. Mullen

Chairman, President, and Chief Executive Officer
David Litvak

David Litvak

Associate Director, Technical Operations
Harry Gill

Harry Gill

Senior Vice President, Operations
Bruce E. Eaton

Bruce E. Eaton

Executive Vice President and Chief Business Officer
Chi Li

Chi Li

Senior Vice President and Chief Regulatory Officer
Mark S. Shearman

Mark S. Shearman

Executive Vice President and Chief Scientific Officer
Show more

Editas Medicine Office Locations

Editas Medicine has offices in Cambridge and Boulder
Cambridge, MA, US (HQ)
11 Hurley St
Boulder, CO, US
Westview building, 4909 Nautilus Ct N 208 211boulder
Cambridge, MA, US
300 Third St
Show all (3)

Editas Medicine Financials and Metrics

Editas Medicine Revenue

Editas Medicine's revenue was reported to be $90.73 m in FY, 2020
USD

Revenue (Q1, 2021)

6.5m

Net income (Q1, 2021)

(56.7m)

EBIT (Q1, 2021)

(56.9m)

Market capitalization (13-May-2022)

811.9m

Closing stock price (13-May-2022)

11.9

Cash (31-Mar-2021)

354.9m

EV

485.9m
Editas Medicine's current market capitalization is $811.9 m.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

6.1m13.7m31.9m20.5m90.7m

General and administrative expense

46.3m50.5m55.0m64.6m67.6m

R&D expense

57.0m83.2m90.7m96.9m158.0m

Operating expense total

103.2m133.7m145.7m161.5m225.6m
Quarterly
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

185.3m146.6m134.8m238.2m139.7m

Accounts Receivable

88.0k679.0k30.0k418.0k6.0m

Prepaid Expenses

2.4m5.8m6.3m10.9m

Inventories

1.8m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(97.2m)(120.3m)(110.0m)(133.7m)(116.0m)

Depreciation and Amortization

2.7m3.3m4.0m

Inventories

1.8m

Accounts Payable

4.6m(1.5m)1.8m274.0k855.0k
USDQ1, 2016

Financial Leverage

1.2 x
Show all financial metrics

Editas Medicine Operating Metrics

FY, 2016

Patents Issued

41

Patents Pending

500
Show all operating metrics

Editas Medicine Cybersecurity Score

Cybersecurity ratingPremium dataset

C

73/100

SecurityScorecard logo

Editas Medicine Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Editas Medicine Online and Social Media Presence

Embed Graph

Editas Medicine News and Updates

Editas Medicine Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Beta Thalassemia

Company on track to dose first transfusion-dependent beta thalassemia patient with EDIT-301 by year-end Company on track to dose first transfusion-dependent beta thalassemia patient with EDIT-301 by year-end

Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the Association for Research in Vison and Ophthalmology Conference

Studies in non-human primates demonstrated nearly 100% gene editing knockout of endogenous RHO gene and more than 30% replacement protein levels

Editas Medicine Announces First Quarter 2022 Results and Business Updates

Appointed Gilmore O’Neill as CEO effective June 1, 2022; James C. Mullen to serve as Executive Chairman

Editas Medicine to Present Pipeline and Platform Data Demonstrating Progress Towards Developing Transformative Gene Editing Medicines at the American Society of Gene and Cell Therapy Annual Meeting

CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that four abstracts have been accepted for presentation, including three oral presentations, at the 25th Annual Meeting of the American Society of Gene and Cel…

Editas Medicine to Host Conference Call Discussing First Quarter 2022 Results and Corporate Update

CAMBRIDGE, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Wednesday, May 4, 2022, at 8:00 a.m. ET to provide a corporate update and results for the first quarter of…

Editas Medicine Receives FDA Rare Pediatric Disease Designation for EDIT-301 for the Treatment of Beta Thalassemia

CAMBRIDGE, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease designation to EDIT-301, an investigational, gene-edited medicine for the tre…
Show more

Editas Medicine Frequently Asked Questions

  • When was Editas Medicine founded?

    Editas Medicine was founded in 2013.

  • Who are Editas Medicine key executives?

    Editas Medicine's key executives are James C. Mullen, David Litvak and Harry Gill.

  • How many employees does Editas Medicine have?

    Editas Medicine has 208 employees.

  • What is Editas Medicine revenue?

    Latest Editas Medicine annual revenue is $90.7 m.

  • What is Editas Medicine revenue per employee?

    Latest Editas Medicine revenue per employee is $436.2 k.

  • Who are Editas Medicine competitors?

    Competitors of Editas Medicine include Biocytogen, Código 46 and TriArm Therapeutics.

  • Where is Editas Medicine headquarters?

    Editas Medicine headquarters is located at 11 Hurley St, Cambridge.

  • Where are Editas Medicine offices?

    Editas Medicine has offices in Cambridge and Boulder.

  • How many offices does Editas Medicine have?

    Editas Medicine has 3 offices.